Personas / Equipo Humano

Jaume Mora Graupera

Buscador de publicaciones

Publicaciones

  • Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Gene-Olaciregui N, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM and Helin K.

    EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas

    NATURE MEDICINE . 23(4): 483-492. Nº de citas: 390

    [doi:10.1038/nm.4293]

  • Huertas-Martínez J, Court F, Rello-Varona S, Herrero-Martín D, Almacellas-Rabaiget O, Sáinz-Jaspeado M, Garcia-Monclús S, Lagares-Tena L, Buj R, Hontecillas-Prieto L, Sastre A, Azorin D, Sanjuan X, López-Alemany R, Moran S, Roma J, Gallego S, Mora J, García Del Muro X, Giangrande PH, Peinado MA, Alonso J, de Alava E, Monk D, Esteller M and Tirado OM.

    DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1

    CANCER LETTERS . 386: 196-207. Nº de citas: 26

    [doi:10.1016/j.canlet.2016.11.020]

  • Monterrubio C, Paco-Mercader S, Gene-Olaciregui N, Pascual-Pastó G, Vilà-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A and Carcaboso AM.

    Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8

    JOURNAL OF CONTROLLED RELEASE . 255: 108-119. Nº de citas: 35

    [doi:10.1016/j.jconrel.2017.04.016]

  • Pascual-Pastó G, Gene-Olaciregui N, Vilà-Ubach M, Paco-Mercader S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacís M, Català-Mora J, Salvador-Hernandez H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada G and Carcaboso AM.

    Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination

    CANCER LETTERS . 380(1): 10-19. Nº de citas: 25

    [doi:10.1016/j.canlet.2016.06.012]

  • Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW and Taylor MD.

    Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis

    JOURNAL OF CLINICAL ONCOLOGY . 34(21): 2468-2477. Nº de citas: 148

    [doi:10.1200/JCO.2015.65.7825]

  • Hernandez-Muñoz I, Figuerola-Bou E, Sánchez-Molina S, Rodriguez E, Fernández-Mariño AI, Pardo-Pastor C, Bahamonde MI, Fernández-Fernández JM, García-Domínguez DJ, Hontecillas-Prieto L, Lavarino C, Carcaboso AM, de Torres C, Tirado OM, de Alava E and Mora J.

    RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoprotein

    Oncotarget . 7(29): 46283-46300. Nº de citas: 12

    [doi:10.18632/oncotarget.10092]

  • Bautista F, Gallego S, Cañete A, Mora J, Diaz de Heredia C, Cruz-Martínez O, Fernández JM, Rives-Solà S, Madero L, Castel V, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M and Moreno L.

    Landscape of early clinical trials for childhood and adolescence cancer in Spain

    CLINICAL & TRANSLATIONAL ONCOLOGY . 18(7): 708-713. Nº de citas: 6

    [doi:10.1007/s12094-015-1421-9]

  • Brandt A, Löhers K, Beier M, Leube B, de Torres C, Mora J, Arora P, Jat PS and Royer-Pokora B.

    Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15

    PLoS One . 11(5): . Nº de citas: 6

    [doi:10.1371/journal.pone.0155561]

  • Mora J.

    Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma

    EXPERT REVIEW OF CLINICAL PHARMACOLOGY . 9(5): 647-653. Nº de citas: 39

    [doi:10.1586/17512433.2016.1160775]

  • Millan NC, Poveda MJ, Cruz-Martínez O and Mora J.

    Safety of bevacizumab in patients younger than 4 years of age

    CLINICAL & TRANSLATIONAL ONCOLOGY . 18(5): 464-468. Nº de citas: 11

    [doi:10.1007/s12094-015-1389-5]